01 — What is it?
Long-acting GHRH analogue studied for increasing GH and IGF-1 exposure. Not an FDA-approved drug.
Database / Research Profiles / CJC-1295
RESEARCH PROFILE
CJC-1295
Growth-hormone-releasing hormone analogue
GH axisEarly human / investigational
EVIDENCE SNAPSHOTEARLY HUMAN / INVESTIGATIONAL
Human pharmacology studies exist, but clinical efficacy/safety for common wellness claims are not established.
Research-first: This profile summarizes published evidence and regulatory context. It is educational reference material, not a diagnosis, treatment recommendation, or personalized dosing protocol.
02 — Research category
GH axis. Evidence strength is based on the availability and quality of human clinical data, not on popularity in the research-peptide market.
03 — Evidence map
Human evidence: LIMITED / NONEPreclinical evidence: SUPPLEMENTALPersonal dosing protocol: NOT PROVIDED
Human pharmacology studies exist, but clinical efficacy/safety for common wellness claims are not established.
04 — Mechanism / biology
Long-acting GHRH analogue studied for increasing GH and IGF-1 exposure. Not an FDA-approved drug.
05 — Safety & limitations
Safety depends on the exact molecule, formulation, route, dose, indication and study population. Research-market products may differ in identity, purity, sterility or stability from materials used in published trials. Absence of reported adverse events in a small study does not establish long-term safety.
06 — Regulatory context
Regulatory status varies by compound and jurisdiction. Where an approved product exists, its approval applies only to specified formulations and indications. Investigational or research-market status should not be presented as equivalent to approval.